Should I Buy PACB? PACB 2026 Analysis

Should You Buy Pacific Biosciences of California Inc (PACB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.370

1 Day change

-0.42%

52 Week Range

2.730

Analysis Updated At

2026/01/26

Pacific Biosciences of California Inc (PACB) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently experiencing a downward trend in price, and while there are some positive indicators such as bullish moving averages and improved gross margin, the negative financial performance, lack of recent news catalysts, and neutral sentiment from hedge funds and insiders suggest that it may be better to wait for clearer signs of recovery or growth before investing.

Technical Analysis

The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating a positive long-term trend. However, the MACD histogram is positively contracting, and the RSI is neutral at 70.594. The stock is trading near its resistance level (R1: 2.631), which may limit immediate upward potential. Overall, technical indicators suggest a mixed outlook.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Bullish moving averages indicate potential long-term upward momentum.
Gross margin increased significantly YoY, showing operational improvements.

Neutral/Negative Catalysts

Revenue, net income, and EPS all declined significantly YoY in Q3 2025, indicating weak financial performance.
No recent news or event-driven catalysts to drive investor sentiment.
Hedge funds and insiders remain neutral with no significant trading activity.

Financial Performance

In Q3 2025, revenue dropped by -3.82% YoY to $38.44M. Net income fell by -37.42% YoY to -$38M, and EPS declined by -40.91% YoY to -0.13. However, gross margin improved significantly to 50.84%, up 219.75% YoY, indicating better cost management.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have raised price targets recently, with Barclays increasing it to $2 from $1.50 and maintaining an Equal Weight rating. Piper Sandler and Stephens also raised their targets to $2, citing potential upside from Revio utilization and NIH clarity. However, the ratings remain mixed, with Neutral and Equal Weight dominating.

5 Analyst Rating

Wall Street analysts forecast PACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB is 2.4 USD with a low forecast of 2 USD and a high forecast of 3 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

2 Hold

0 Sell

Moderate Buy

Current: 2.380

Low

Averages

2.4

High

Current: 2.380

Low

Averages

2.4

High

Barclays

Luke Sergott

Equal Weight

maintain

AI Analysis

2025-12-15

Reason

Barclays

Luke Sergott

Price Target

AI Analysis

2025-12-15

maintain

Equal Weight

Reason

Barclays analyst Luke Sergott raised the firm's price target on PacBio to $2 from $1.50 and keeps an Equal Weight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Piper Sandler

Neutral

maintain

2025-11-11

Reason

Piper Sandler

Price Target

2025-11-11

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on PacBio to $2 from $1.50 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PACB

Unlock Now

PACB Should I Buy

PACB Should I Buy

Should You Buy Pacific Biosciences of California Inc (PACB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch